Delayed Sleep Phase clinical trials at UCSF
2 research studies open to eligible people
Lemborexant in Delayed Sleep Phase Syndrome
open to eligible people ages 18 years and up
The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, we will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.
Redwood City, California
The Reducing Risk Study
open to eligible people ages 12-18
The present study will test an innovative mobile health adaptation of a behavioral intervention that improves sleep and mental health concerns among adolescents.
San Francisco, California
Our lead scientists for Delayed Sleep Phase research studies include Lauren Asarnow, PhD.